SGCG and familial pancreatic carcinoma: Bintrafusp alfa (M7824) is a bifunctional fusion protein with a type II TGF-β receptor fused to an antibody against PD-L1 (Figure 1B) (102), which has undergone a phase 1 clinical trial (NCT02517398) that included five patients with pancreatic cancer.